PT - JOURNAL ARTICLE AU - Kannoth, Sneha AU - Kandula, Sasikiran AU - Shaman, Jeffrey TI - The Association between Early Country-level Testing Capacity and Later COVID-19 Mortality Outcomes AID - 10.1101/2021.01.18.21249998 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.18.21249998 4099 - http://medrxiv.org/content/early/2021/01/20/2021.01.18.21249998.short 4100 - http://medrxiv.org/content/early/2021/01/20/2021.01.18.21249998.full AB - Background The COVID-19 pandemic has overrun hospital systems while exacerbating economic hardship and food insecurity on a global scale. In an effort to understand how early action to find and control the virus is associated with cumulative outcomes, we explored how country-level testing capacity affects later COVID-19 mortality.Methods We used the Our World in Data database to explore testing and mortality records in 27 countries from December 31, 2019 to September 30, 2020; we applied ordinary-least squares regression with clustering on country to determine the association between early COVID-19 testing capacity (cumulative tests per case) and later COVID-19 mortality (time to specified mortality thresholds), adjusting for country-level confounders, including median age, GDP, hospital bed capacity, population density, and non-pharmaceutical interventions.Results Higher early testing implementation, as indicated by more cumulative tests per case when mortality was still low, was associated with longer accrual time for higher per capita deaths. For instance, a higher cumulative number of tests administered per case at the time of 6 deaths per million persons was positively predictive of a longer time to reach 15 deaths per million, after adjustment for all confounders (β=0.659; P=0.001).Conclusions Countries that developed stronger COVID-19 testing capacity at early timepoints, as measured by tests administered per case identified, experienced a slower increase of deaths per capita. Thus, this study operationalizes the value of testing and provides empirical evidence that stronger testing capacity at early timepoints is associated with reduced mortality and better pandemic control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study does not require ethics review given that it uses publicly available and accessible records without contact with the individuals.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are publicly available in the 'Our World in Data' database [https://ourworldindata.org/coronavirus], and the 'Worldwide Non-pharmaceutical Interventions Tracker for COVID-19' database [https://ibm.github.io/wntrac/dataset]. https://ourworldindata.org/ https://ibm.github.io/wntrac/dataset/